Search
Showing results for "clinical trials"
Christopher Jennifer Peter Blyth Kent Richmond MBBS (Hons) DCH FRACP FRCPA PhD RN MBBS MRCP(UK) FRACP Centre Head, Wesfarmers Centre of Vaccines and
Head-mounted devices (HMDs) have been explored in anaesthesia education for their unique ability to have head-tracked immersive simulations adaptable to diverse clinical scenarios. This scoping review examines how HMD-based augmented or virtual reality enhances anaesthetic skill learning in clinicians, trainees, and students.
The Opportunity To be involved with clinical trials that are a part of the Childhood Allergy and Immunology Research (CAIR) Group, run out of the
Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Honorary and NHMRC Career Development Fellow, Paediatric Infectious Diseases Physician and Clinical Microbiologist
A Perth study has shown that over-the-counter asthma medication before surgery can reduce respiratory complications during and after tonsillectomy surgery.
Introduction Grades 2 and 3 gliomas (G2/3 gliomas), when combined, are the second largest group of malignant brain tumours in adults. The outcomes for G2/3 gliomas at progression approach the dismal outcomes for glioblastoma (GBM), yet there is a paucity of trials for Australian patients with relapsed G2/3 gliomas compared with patients with GBM.
The placebo effect is established in clinical trials, but for paediatric research, questions remain about how to best manage its influence. Within the autism field, data on these issues is sparse. This is particularly important in the oxytocin field where placebo responses are thought to play an important role. This study reports on data from the single-blind, placebo lead-in phase of a randomised controlled trial to investigate the placebo response and its relationship to treatment response in autistic children.
The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTKs) consists of EGFR, ErbB2, ErbB3, and ErbB4. These receptors play key roles in cell proliferation, angiogenesis, cell migration, and in some cases, tumor promotion.
We found two known risk factors in a large cohort of children treated for ALL and identified other factors associated with venous thromboembolism
Medulloblastoma is the most common childhood brain cancer. Mainstay treatments of radiation and chemotherapy have not changed in decades and new treatment approaches are crucial for the improvement of clinical outcomes. To date, immunotherapies for medulloblastoma have been unsuccessful, and studies investigating the immune microenvironment of the disease and the impact of current therapies are limited.